Poseida Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 330
- Market Cap
- $272.9M
- Website
- http://www.poseida.com
- Introduction
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in December 2014 and is headquartered in San Diego, CA.
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Poseida Therapeutics, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06014762
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸Prisma Health - Upstate Cancer Institute, Greenville, South Carolina, United States
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Poseida Therapeutics, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05239143
- Locations
- 🇺🇸
University of California, Irvine Medical Center, Irvine, California, United States
🇺🇸University of Maryland Cancer Center, Baltimore, Maryland, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-07-14
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Poseida Therapeutics, Inc.
- Target Recruit Count
- 231
- Registration Number
- NCT04960579
- Locations
- 🇺🇸
Advocate Aurora Health, Park Ridge, Illinois, United States
🇺🇸University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
- Conditions
- Interventions
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Poseida Therapeutics, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04249947
- Locations
- 🇺🇸
University of California San Diego, San Diego, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
- Conditions
- Interventions
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Poseida Therapeutics, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT03741127
- Locations
- 🇺🇸
Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸University of California, San Diego, San Diego, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)
- Conditions
- Interventions
- First Posted Date
- 2017-09-20
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Poseida Therapeutics, Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT03288493
- Locations
- 🇺🇸
Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸University of California San Diego, San Diego, California, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States